知名医美巨头，涉嫌严重造假？官方回应→

Core Viewpoint - The article discusses the recent controversy surrounding Juzhibio's product quality and testing methods, particularly related to its flagship brand Kefu Mei, which significantly impacts the company's revenue and stock performance [3][6]. Company Overview - Juzhibio's flagship brand Kefu Mei contributes over 80% of the company's revenue, with 2024 revenue reported at 5.539 billion yuan and net profit at 2.062 billion yuan, where Kefu Mei's revenue alone was 4.542 billion yuan, accounting for 82% of total revenue [6]. - The company was established in September 2001, with a registered capital of approximately 688 million yuan, and operates in various sectors including medical devices and daily chemical products [7]. Recent Controversy - Beauty blogger Dazui Doctor has raised concerns about Juzhibio's testing methods, claiming that the use of biuret could lead to inflated test results due to the presence of sodium polyglutamate in Kefu Mei products [3]. - Following criticism from Huaxi Biological on May 17, Juzhibio's stock price dropped significantly, with a market value decline noted [6]. - The ranking of Kefu Mei on Tmall's 618 promotion list fell from 7th to 12th, indicating a potential loss of consumer confidence [6]. Regulatory Response - The Xi'an Market Supervision Bureau has acknowledged the situation and is conducting investigations, although cosmetic regulation falls under higher authorities [6]. - The Shaanxi provincial regulatory department has also stated that they are looking into the matter [6]. Product Availability - Feedback from consumers indicates that the original version of Kefu Mei's collagen repair essence is no longer available on major e-commerce platforms, while the newer version remains for sale [7]. Intellectual Property and Business Structure - Juzhibio has applied for multiple trademarks related to Kefu Mei, with many successfully registered, and holds over 120 patents, primarily in the fields of recombinant collagen and immune-boosting compositions [9].